An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02811159
Recruitment Status : Terminated (Business decision)
First Posted : June 23, 2016
Last Update Posted : June 5, 2018
Information provided by (Responsible Party):
Repros Therapeutics Inc.

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : May 31, 2017
  Actual Study Completion Date : May 31, 2017
  Certification/Extension First Submitted : May 31, 2018